Back to the main directory
Company Analysis / Equity
- NOVARTIS (BUY, TP CHF115) | Towards the end of canakinumab in oncology? by Bryan Garnier
- DASSAULT SYSTÈMES - BUY | EUR52 (+10%) A very solid Q3 and increase guidance for the full-year by Bryan Garnier
- NEMETSCHEK - BUY | EUR98 (-5%) A solid quarter driven by Build and transition to subscriptions in Media & Entertainment by Bryan Garnier
- DVS Technology - Recovering markets support results by Edison Investment Research
- CI Games - Strong Q321 update, third title in development by Edison Investment Research
- Pan African Resources - Everything falling into place by Edison Investment Research
- Worldline: In troubled waters, but the horizon is clearing up | BUY | EUR86 VS. EUR93 (+56%) by Bryan Garnier
- GRANDVISION (BUY, TP EUR28) | Q3 results confirm the sales and earnings sequential improvement by Bryan Garnier
- CARLSBERG (BUY Top Picks, TP DKK1200) | Impact of acquisitions on top of strong organic Q3 by Bryan Garnier
- INDRA SISTEMAS: Another strong quarter, new guidance increase, and a dividend | BUY Top Picks | EUR13 VS. EUR12 (+36%) by Bryan Garnier
- ACCOR (SELL, TP EUR26.5) | Feedback CC Q3 sales: An undeniable improvement but still a long way to go: by Bryan Garnier
- NOTE - NRJ Group - Acheter, Initiation de Couverture - Obj. 10€ by Portzamparc
- SENSORION - CORPORATE | EUR6(+217%) KOL Call Report: Cisplatin-induced ototoxicity offers a promising opportunity for SENS-401 by Bryan Garnier
- DASSAULT SYSTÈMES - BUY | EUR54 VS. EUR52 (+8%) Managing expectations properly by Bryan Garnier
- MATERIALISE: Recovery is confirmed, driven by the Manufacturing division | BUY | USD36 VS. USD38 (+43%) by Bryan Garnier
- ROCHE BOBOIS: Order backlog is surprisingly still increasing sequentially in Q3 | BUY | EUR37 VS. EUR34 (-5%) by Bryan Garnier
- Heliad Equity Partners - New investments under new management by Edison Investment Research
- Creo - Unlocking the potential of rare cannabinoids by Edison Investment Research
- Newron Pharmaceuticals - Pivotal progress on schizophrenia therapy by Edison Investment Research
- CentralNic Group - Growth at an attractive valuation by Edison Investment Research
- ScotGems - Focused portfolio with initial Asia ex-Japan/EM tilt by Edison Investment Research
- SynBiotic - Building a cannabis platform by Edison Investment Research
- EKINOPS (Conviction BUY Top Picks, TP EUR10) | Seizing opportunities from edge computing software business by Bryan Garnier
- Mensch & Maschine Software - FY21 outlook confirmed by Edison Investment Research
- HELLOFRESH: Third sales guidance upgrade of the year in a row | BUY | EUR100(+32%) by Bryan Garnier